Global Life Science Hub’s Post

🤝 $𝟏.𝟏 𝐁𝐢𝐥𝐥𝐢𝐨𝐧 𝐚𝐜𝐪𝐮𝐢𝐬𝐢𝐭𝐢𝐨𝐧 𝐨𝐟 Avid Bioservices!! 🤑 𝗪𝗵𝗼?? 💰 - GHO Capital Partners LLP and Ampersand Capital Partners, leading healthcare and CDMO investment advisors. 𝗪𝗵𝘆?? 🤔 - This allows Avid to build on their strong foundation by accessing Ampersand and GHO's significant knowledge base, network and capital to well position the business. 𝗪𝗵𝗮𝘁?? 👨🔬 - Avid operates in high growth markets, producing complex biologics for leading pharmaceutical and biotech innovators at both the clinical and commercial stages. 𝗪𝗵𝗲𝗻?? 📅 - First quatre of 2025 (subject to conditions) I will certainly be keeping an eye on Avid, big things to come...!! #CDMO #AvidBioservices #GHOcapital #AmpersandCapital

Genmab, Kintara, Ginkgo and More Continue 2024 M&A Upswing | BioSpace https://lnkd.in/g55mRA5Y Pictured: A collage of biopharma M&A/ Nicole Bean for BioSpace After a slow 2022 and early part of 2023, the pace of mergers and acquisitions in the pharmaceutical and biotech sectors has accelerated since the [...]

Genmab, Kintara, Ginkgo and More Continue 2024 M&A Upswing | BioSpace https://lnkd.in/gaPUd72g Pictured: A collage of biopharma M&A/ Nicole Bean for BioSpace After a slow 2022 and early part of 2023, the pace of mergers and acquisitions in the pharmaceutical and biotech sectors has accelerated since the [...]

Sequent Scientific ltd Market capitalisation:48.76 bn Nifty :26,240 "Sequent Scientific, Viyash Life Sciences announce Rs 8,000 crore merger" 📍Merger Announcement: Sequent Scientific and Viyash Life Sciences are merging in a deal valued at Rs 8,000 crore. 📍Strategic Goals: The merger aims to enhance capabilities and expand product offerings in the pharmaceutical sector. 📍Market Impact: The combined entity is expected to strengthen market position and drive growth in the biotech industry. 📍Operational Synergies: The merger will leverage operational efficiencies and broaden research and development capabilities. 📍Future Plans: Leadership anticipates accelerated innovation and improved service delivery post-merger. Rishabh Kale

🚨 **Avid Bioservices to Go Private in $1.1B Acquisition Deal** 🚨 Avid Bioservices, a leading biologics-focused contract development and manufacturing organization (CDMO), has entered into an agreement to be acquired by GHO Capital Partners and Ampersand Capital Partners in an all-cash transaction valued at approximately $1.1 billion. Under the deal, Avid’s Nasdaq-listed shares will be acquired for $12.50 per share, a 13.8% premium over the company’s closing price on November 6, 2024. Once the deal is finalized in Q1 2025, Avid will become a privately held entity, continuing to operate under its established brand and leadership. As a trusted provider of process development and CGMP manufacturing services for biotech and biopharma, Avid has seen significant growth, including a 6% increase in revenue in Q1 FY2025. Its strong order backlog, coupled with strategic investments in capacity and team development, position the company for continued success. **Nick Green**, President and CEO of Avid, shared, "Partnering with GHO and Ampersand will allow us to build on our strong foundation and further accelerate growth with the support of their capital and expertise." This acquisition reflects the growing demand for high-quality, efficient manufacturing of biologic therapies and further strengthens Avid’s position in the rapidly expanding biotech market. #Biotech #CDMO #AvidBioservices #Acquisition #Biopharma #HealthcareInnovation #Manufacturing #GHO #AmpersandCapital #PrivateEquity #LifeSciences #BusinessGrowth

🔔 OrbiMed has closed more than $4 billion in fresh commitments after a reliable year of acquisitions in the pharmaceutical and biotech industries. Pitchbook has shared an article reflecting the hype caused by the healthcare investor OrbiMed's recent success in raising its 'trio of funds' in its ninth US-focused venture. 'Drug and therapeutics innovation—combined with pharma and biotech M&A deals that are freeing up LP cash—are driving capital commitments in a dry market.' Read the article to find out more - https://bit.ly/3ML2lNo. Want to invest? Discover the latest deals in the Scherzer Deal Report, delivered every Wednesday - https://bit.ly/49EZH5F #Merger #Acquisition #Pharma #Biotech #ScherzerDealReport

There were 13 biopharma M&A deals in Q1 of 2024, more than doubling what we saw in Q1 of 2023. Radiopharmaceuticals and ADC are trending targets this year for acquisitions. Read more about #M&A trends in the Fierce Biotech article below. #biotech

🔔 Semnur Pharmaceuticals Going Public Through SPAC Merger Big news from Semnur Pharmaceuticals! They announced they are going public by merging with Denali Capital Acquisition Corp, a SPAC (special purpose acquisition company). This deal values Semnur at up to $2 billion. ✅ Semnur, which develops non-opioid pain treatments, will continue to operate under its name with Scilex Holding as the main shareholder if the deal gets approved. They hope to get the green light from Denali’s shareholders by the second half of 2024. 🦵 The money from this merger will help fund their top drug candidate, SP-102, currently in late-stage trials for sciatica. Sciatica causes pain due to nerve issues in the lower back and legs. 💪 I think that using a SPAC to go public can be quicker and offer more flexibility than a traditional IPO. A $2 billion valuation shows strong confidence in their future, especially with their focus on non-opioid pain solutions. But, there are risks. SPACs need to complete deals within a certain time, and aligning shareholder interests can be tricky. If successful, though, Semnur will have the funds they need to push their drug developments forward. 🤔 What do you think about Semnur's plan to go public? #Pharmaceuticals #SPAC #Biotech #Investment #MicroCap #IPO #Investing #StockMarket Read more: https://lnkd.in/dU7B3M2x

The 2023 acquisition trend is definitely continuing with the start of 2024. See the image below. It could be considered "common knowledge" that big pharma companies have been reassessing long-term revenue streams and redirecting efforts to more sustainable options. The concern or need for tighter control has also been at the forefront. Additionally, patent expirations are up later this decade. Acquisition of later-stage assets to fill up development pipelines seem to be a logical next step for many of them. "The CymaBay deal, expected to close this quarter, follows a series of high-profile acquisitions at the end of 2023, a few bolt-on deals during the JP Morgan Healthcare Conference, and Novartis’ $2.9 billion MorphoSys bid last week." You can read more about this latest deal via the link in the comments section. #biopharma #acquisitions #markettrends #productpipelines #drugmakers #science #research #pharmaceuticals #cellandgenetherapy

What is the average Value of Priority Research Voucher? Recently X4Pharma announced the sale of their PRV for USD 105m. This comes only a few months after the sale of a PRV by Valneva in February 2024 for USD 103m. So what is the average value of a PRV in recent years? GlobalData analysed 19 deals where the buyer of vouchers was made public, and where vouchers were sold solely as assets – as opposed to being grouped within an acquisition, merger, or license deal. The first ever PRV sale took place in 2014 when BioMarin sold theirs to Regeneron Pharmaceuticals for $67.5 million. Since 2015, the secondary market for priority review vouchers has stabilised and these now go for an average amount of $100 million.